In 2012, Pieter van Bokhoven obtained his PhD title in molecular neurobiology at the Vrije Universiteit Amsterdam. He broadened his experience towards business as an entrepreneur and founding partner of an SME developing applications for pharmaceutical companies. In 2015, van Bokhoven decided to focus his career towards collaborations on drug development between industry and academia. He specializes in business development towards preclinical and clinical drug development for brain diseases, in particular Alzheimer’s Disease and other dementias. In previous years, van Bokhoven worked as Director of Business development for Amsterdam Neuroscience.
As of November 1, 2021, van Bokhoven will take up the position of CSO. With the IAO team, consisting of a legal and financial back office and the business development front office they will continue to speed up the development of new therapies and diagnostics for patients suffering from a neurological disorder or mental illness, from bench to bedside.
Pieter van Bokhoven: “I’m very excited about my new role as CSO as it allows me to think strategically about drug development for brain diseases here at Amsterdam Neuroscience and in collaboration with industry.”
Meet the Industry Alliance Office of Amsterdam Neuroscience:
Or read the latest work of Pieter van Bokhoven and his colleagues in their recently published review on the Alzheimer’s drug development landscape. Or read more on work of the Industry Alliance Office.
